New York, Jan. 13, 2020 (GLOBE NEWSWIRE) -- The global Insulin Market is forecast to reach USD 35.74 Billion by 2027, according to a new report by Reports and Data. Insulin therapy is used for the treatment of patients with all types of diabetes.

The need for insulin therapy depends upon the balance between insulin resistance and insulin secretion. Patients with type 1 diabetes require insulin treatment permanently unless they receive a whole organ pancreas transplant or an islet. Type 2 diabetes patients require insulin as their beta-cell function lowers over time.

Diabetes and its complications, societal costs, and deaths have a huge and rapidly growing impact across the globe. In 2019: approximate 463 million adults (20-79 years) were living with diabetes and by 2045 this is expected to rise to 700 million. A growing number of diabetic patients are propelling the demand for insulin.

Request free sample of this research report at: https://www.reportsanddata.com/sample-enquiry-form/2338

The market in Asia Pacific is estimated to witness an increasing demand in the forecast period owing to growing awareness pertaining to medical treatments and care, rising health care sector, and an increase in R&D activities. Further, a rapid increase in the diabetic population and increasing adoption of insulin administration are driving the market demand in the region.

Further key findings from the report suggest

  • The reason healthcare providers prescribe care users medications that can be injected with the help of an insulin pen is, the patient can inject the medicine himself/herself. The ability of care users to take medicine on their own and incorporate it in-home healthcare results in enhanced care user's adherence to care regimes that improve their quality of life and minimizes healthcare costs.
  • An insulin pump is a delivery device that pushes small, steady doses of rapid-acting insulin into a thin tube and is inserted underneath the patient's skin. There are several different kinds of insulin pumps available. These dosages are delivered repeatedly throughout the day.
  • Biosimilar insulins are a biological copy of an original insulin, and there is an increasing interest in developing and using them. These insulins are cheaper than original products, so they present the NHS with opportunities around availability and cost of care. However, there is a lack of awareness among healthcare professionals and people with diabetes about their use.
  • People with type 2 diabetes are able to manage their blood glucose levels with oral medication and lifestyle changes. However, if these treatments don’t help in controlling their level of glucose, people with the condition are also given shots of insulin to help control their blood glucose levels.
  • North America holds the largest share as of 2018 because of an increasing incidence of diabetes in the region. Government initiatives to spread awareness about the product along with a favorable funding from many private players are leading the market growth.
  • Key participants include Novo Nordisk A/S, Sanofi, Eli Lily and Company, ADOCIA, Julphar, Pfizer, Inc., Oramed Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Merck & Co., Inc., and GlaxoSmithKline Plc, among others.

To identify the key trends in the industry, click on the link below:   https://www.reportsanddata.com/report-detail/insulin-market

Segments covered in the report:

For the purpose of this report, Reports and Data have segmented into the global Insulin Market on the basis of product type, diseases, delivery devices, end-users, and region:                     

Product Type Outlook (Revenue, USD Billion; 2016-2027)

  • Basal or Long-Acting Insulin
  • Bolus or Fast-Acting Insulin
  • Traditional Human Insulin
  • Combination Insulin
  • Biosimilar Insulin

Diseases Outlook (Revenue, USD Billion; 2016-2027)

  • Type 1 Diabetes
  • Type 2 Diabetes
  • Gestational Diabetes
  • Prediabetes

Delivery Devices Outlook (Revenue, USD Billion; 2016-2027)

  • Syringes
  • Pens
  • Pumps
  • Others

End-Users Outlook (Revenue, USD Billion; 2016-2027)

  • Home healthcare
  • Hospitals
  • Over the counter (OTC)
  • Clinics
  • Others

Order Now: https://www.reportsanddata.com/checkout-form/2338

Regional Outlook (Revenue in USD Billion; 2016–2026)

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Spain
    • Italy
    • Rest of the Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Rest of Asia-Pacific
  • Middle East & Africa
    • Latin America
  • Brazil

Browse more similar reports on Biotechnology category by Reports And Data

In vivo CRO Market - https://www.reportsanddata.com/report-detail/in-vivo-cro-market

Cell Surface Markers Market - https://www.reportsanddata.com/report-detail/cell-surface-markers-market

Gene Expression Market - https://www.reportsanddata.com/report-detail/gene-expression-market

About Reports and Data

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client’s make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power, and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise.

Contact Us:
John Watson
Head of Business Development
Reports And Data | Web: www.reportsanddata.com
Direct Line: +1-800-819-3052
E-mail: sales@reportsanddata.com